John Newman

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) said Wednesday that it requested emergency use authorization from the FDA for its investigational coronavirus antibody cocktail. The experimental drug, named REGN-COV2, was in news last week after it was administered to President...

Canaccord Genuity is maintaining its bullish stance on bluebird bio Inc (NASDAQ: BLUE) and projects upside for the biotech following a positive patient response to bb2121, the company’s multiple myeloma treatment. The Analyst  John Newman maintains a Buy rating on bluebird bio...

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) shares fell 31 percent over the last six months, and the company's headwinds appear unending. The biotech firm lost an advocate Wednesday on the basis of a rough outlook for Eylea and Dupixent treatments. The Rating Canaccord Genuity analyst John...

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced results Monday from two mid-stage studies for diabetic macular edema and age-related macular degeneration therapies. The combo did not provide sufficient differentiation to warrant a Phase 3 development,Regeneron said. The Analyst Canaccord...

Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) fell 2.6 percent Wednesday as the Street reacted to an ostensible downgrade. Canaccord Genuity’s John Newman had long been confidently bullish on the stock, so when a new note updated coverage with a “speculative” Buy, traders...

Canaccord Genuity analyst John Newman maintains his Buy rating and price target of $85 on Radius Health Inc (NASDAQ: RDUS). Newman stated, “We continue to believe that RDUS' Tymlos will become an important therapy in the osteoporosis market, increasing shareholder value. We also believe...

Canaccord Genuity said it views Takeda Pharmaceutical Co Ltd (ADR) (OTC: TKPYY)’s speculated interest in buying Synergy Pharmaceuticals Inc (NASDAQ: SGYP) as a positive step. The potential deal could boost its GI (gastrointestine) portfolio. Speculative Interest Commenting on the indication...

Canaccord Genuity said safety remains a critical concern for the potential success of KTE-C19 following Kite Pharma Inc (NASDAQ: KITE) presenting updated data through 12 months from its Phase 1 ZUMA-1 trial in chemorefractory, aggressive non-hodgkin's lymphoma. The firm noted that the trail showed...

Canaccord Genuity said Gemphire Therapeutics Inc (NASDAQ: GEMP)'s oral cholesterol drug Gemcabene has a peak U.S. market potential of $2.8 billion. The firm initiated coverage of the stock with a Buy rating. The brokerage also set a price target of $17, implying a potential upside of 67 percent...

Agios Pharmaceuticals Inc (NASDAQ: AGIO) presented the Phase 2a data for AG-348 at the EHA in Copenhagen. The data demonstrates a significant increase in hemoglobin levels, establishing proof of concept. Canaccord Genuity’s John Newman upgraded the rating on the company from Hold to Buy,...

Canaccord Genuity’s John Newman maintained a Hold rating on Medivation Inc (NASDAQ: MDVN), with a price target of $45. March-In Hearing “We do not expect any meaningful price changes for Xtandi based on a request from six US senators for a public hearing to consider "march-in...